Whitehawk Therapeutics (WHWK) Current Deferred Revenue (2018)

Whitehawk Therapeutics' (WHWK) quarterly Current Deferred Revenue came in at $18.7 million in Q2 2018.

Whitehawk Therapeutics (WHWK) Current Deferred Revenue (2018) Analysis & Trends

Whitehawk Therapeutics (WHWK) has 1 years of Current Deferred Revenue data on file, last reported at $18.7 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Whitehawk Therapeutics	34.18 Mn	34.18 Mn	-

Download Data

Date	Value
Jun 30, 2018	18.67 Mn